Literature DB >> 2646653

Drug metabolism in liver disease.

C W Howden1, G G Birnie, M J Brodie.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2646653     DOI： 10.1016/0163-7258(89)90088-0

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


× No keyword cloud information.
  18 in total

Review 1.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

2.  Pharmacokinetics of metoclopramide in patients with liver cirrhosis.

Authors:  E Magueur; H Hagege; P Attali; E Singlas; J P Etienne; A M Taburet
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

3.  Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.

Authors:  J I Macdonald; S M Wallace; V Mahachai; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Disposition of antipyrine in patients with extensive metastatic liver disease.

Authors:  G M Robertz-Vaupel; K D Lindecken; T Edeki; C Funke; S Belwon; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 6.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

7.  Conjugation pathways in liver disease.

Authors:  G M Pacifici; A Viani; M Franchi; S Santerini; A Temellini; L Giuliani; M Carrai
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

8.  Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers.

Authors:  G P Pageaux; J Micallef; M B Nataf; J C Levron; B Lacarelle; J P Le Moing; P Bouhours; O Blin
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 9.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

10.  The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.

Authors:  J C Blake; J L Palmer; N A Minton; A K Burroughs
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.